![]() |
|
|
Molecular Pharmacology, Vol 12, 789-799, Copyright © 1976 by the American Society for Pharmacology and Experimental Therapeutics
1 Departments of Pharmacology and Medicine, University of North Carolina School of Medicine, Chapel Hill,
North Carolina 27514
Human ACTH and a number of ACTH peptide fragments were prepared by solid-phase
synthesis. Of the analogues tested, only ACTH1-39 and ACTH1-24 stimulated rat adrenal
membrane adenylate cyclase in vitro. Several shorter fragments, including ACTH6-39,
ACTH9-24, ACTH9-19 amide, ACTH9-20, ACTH9-18, and ACTH12-39, inhibited stimulation
of the enzyme by native bovine ACTH. The inhibition produced by this group of peptides
appears to be specific for ACTH-stimulated adrenal adenylate cyclase. Basal and
fluoride-stimulated enzyme activity in adrenal and fluoride- or epinephrine-stimulated
activity in liver were not inhibited by ACTH9-24. To elucidate further the action of the
inhibitory peptides, we tested their ability to inhibit the binding of [125I]ACTH1-24 to
adrenal particles. Peptides having either agonist or antagonist activity in the adenylate
cyclase assay were effective competitors for binding. The order of potency according to
both adenylate cyclase inhibition and competitive binding affinity was ACTH6-39 >
ACTH9-19 amide
ACTH9-24 > ACTH9-20
ACTH9-18 > ACTH12-39. The analogues
ACTH1-8, ACTH9-16, and ACTH19-39 were inactive in both the adenylate cyclase and
binding systems. Comparison of this series of closely related peptides in two independent
assay systems should more clearly define the structural requirements for the binding of
ACTH to its membrane receptor.